[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Ningbo No.2 Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":123},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,39,70,94],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":4},"100639885","cohort-of-lower-extremity-sports-injuries-and-degenerationyongjiang-cohort-100639885",false,"NCT07592871","Cohort of Lower-Extremity Sports Injuries and Degeneration(Yongjiang Cohort)","Bidirectional Cohort of Lower-Extremity Sports Injuries and Degeneration (Yongjiang Cohort)","Inclusion Criteria:\n\n* Patients who plan to receive relevant clinical evaluation or treatment at Ningbo No. 2 Hospital and are able to complete baseline assessment.\n* Patients with a clinical diagnosis of knee-related injury or degenerative knee disease.\n* Patients who are willing to provide informed consent and participate in follow-up.\n\nExclusion Criteria:\n\n* Patients who are unable to complete the core baseline assessments or have substantial missing key clinical information.\n* Patients with severe comorbid conditions or cognitive impairment that may affect assessment of the main outcomes or prevent participation in follow-up.\n* Patients who are considered by the investigator to be unsuitable for inclusion in this cohort.","ALL","18 Years","90 Years",{"count":20,"type":21},500,"ESTIMATED","2 Years","OBSERVATIONAL","This is an observational cohort study conducted at Ningbo No. 2 Hospital. The study will include patients with knee-related sports injuries or degenerative knee conditions who receive routine clinical care. The purpose is to build a standardized real-world clinical cohort and evaluate knee injury, degeneration, recovery, and long-term outcomes.\n\nAfter informed consent, participants will undergo baseline data collection, including medical history, laboratory tests, questionnaires, X-ray and MRI imaging, and functional assessments. Patients younger than 50 years will mainly be assessed for sports injury and functional recovery, while patients aged 50 years or older will receive additional sarcopenia-related assessments such as grip strength, DXA testing, and gait evaluation.\n\nNo experimental treatment, randomization, or intervention will be assigned. Participants will be followed at about 6, 12, and 24 months after treatment or surgery to assess knee function, imaging changes, reinjury, reoperation, pain, quality of life, falls, and functional decline. The study plans to enroll about 500 participants.",[26],"Osteoarthritis (OA) of the Knee","NOT_YET_RECRUITING","2026-05-19",{"date":30,"type":31},"2026-05-22","ACTUAL",{"date":33,"type":21},"2026-06-01",{"date":35,"type":21},"2028-05-31",{"name":37,"class":38},"Ningbo No.2 Hospital","OTHER",{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":46,"enrollmentInfo":47,"targetDuration":4,"studyType":49,"phases":50,"briefSummary":52,"conditions":53,"keywords":57,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":5},"100635521","early-phase-1-efficacy-and-safety-of-pegylated-interferon-alpha-2-in-patients-with-hepatitis-b-related-hepatocellular-carcinoma-after-radical-resection-100635521","NCT07553767","Efficacy and Safety of Pegylated Interferon Alpha-2β in Patients With Hepatitis B-related Hepatocellular Carcinoma After Radical Resection","A Non-randomized Controlled, Prospective, Real-world Study to Evaluate the Efficacy and Safety of Pegylated Interferon Alpha-2β in Patients With Hepatitis B-related Hepatocellular Carcinoma After Radical Resection","Inclusion Criteria:\n\n* Age 18 to 65 years, male or female.\n* Confirmed diagnosis of hepatitis B virus-related hepatocellular carcinoma (HCC) by pathology or contrast-enhanced CT\u002FMRI.\n* Underwent radical resection or local ablation therapy; CNLC (Chinese Liver Cancer Classification) stage Ia, Ib, or IIa; no residual tumor confirmed by imaging within 1-3 months postoperation.\n* HBsAg positive and HBsAg level \\\u003C 2000 IU\u002FmL.\n* No prior systemic chemotherapy, immunotherapy, or targeted therapy before enrollment.\n* Able to provide written informed consent and comply with the follow-up schedule.\n* For women of childbearing potential: negative pregnancy test and effective contraception during treatment and for 24 weeks after the last dose.\n\nExclusion Criteria:\n\n* Recurrent or metastatic HCC at enrollment.\n* Contraindication to peginterferon alfa-2b treatment.\n* WBC \\\u003C 3.5×10⁹\u002FL or platelet count \\\u003C 100×10⁹\u002FL.\n* ALT \\> 3×ULN or total bilirubin (TBIL) \\> 2×ULN.\n* Child-Pugh score \\> 5 points.\n* INR \\> 1.5.\n* History of organ transplantation or planned transplantation.\n* Hypersensitivity to peginterferon alfa-2b or any excipient of the study drug.\n* Pregnant or breastfeeding women.\n* Participation in another interventional clinical trial.\n* History of significant alcoholism or drug abuse.\n* Genetic or metabolic liver disease (Wilson disease, hemochromatosis, etc.).\n* Coinfection with HAV, HCV, HEV, EBV, CMV , or other viral hepatitis that may interfere with study evaluation.\n* Unable to comply with study procedures and follow-up.\n* Other conditions deemed inappropriate by the investigator.","65 Years",{"count":48,"type":21},156,"INTERVENTIONAL",[51],"EARLY_PHASE1","The goal of this clinical trial is to evaluate the efficacy and safety of peginterferon alfa-2β (Peg-IFN-α-2β) combined with nucleos(t)ide analogues (NAs) in patients aged 18 to 65 years with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) after radical resection. The main questions it aims to answer are:\n\n* What are the changes in hepatitis B surface antigen (HBsAg) disappearance rate, HBsAg seroconversion rate, HBsAg decline, and hepatitis B virus deoxyribonucleic acid (HBV DNA) levels during treatment and at the end of treatment?\n* What are the 1-year, 2-year, 3-year, and 5-year recurrence-free survival (RFS) and overall survival (OS) of the included patients?\n* What are the correlations between changes in HBsAg, T helper 1\u002FT helper 2 (Th1\u002FTh2) subsets, intestinal flora and RFS, OS in these patients?\n\nResearchers will compare Peg-IFN-α-2β combined with NAs to NAs alone to see if the combination treatment can improve HBsAg clearance, seroconversion, long-term survival and reduce recurrence in patients after radical resection of hepatitis B-related hepatocellular carcinoma.\n\nParticipants will:\n\n* Receive either Peg-IFN-α-2β combined with first-line NAs (tenofovir disoproxil fumarate \\[TDF\\], tenofovir alafenamide fumarate \\[TAF\\], tenofovir amibufen fumarate \\[TMF\\]) or first-line NAs alone\n* Undergo regular assessments including HBsAg, HBV DNA, liver and renal function, blood routine, thyroid function, autoantibodies, and tumor markers\n* Provide stool samples for intestinal flora analysis at specified time points\n* Complete long-term survival follow-up for up to 5 years",[54,55,56],"Hepatocellular Carcinoma","HEPATITIS B CHRONIC","Hepatitis B Chronic Infection",[58,59,60,61],"Peg-IFN-α-2b","hepatitis B","hepatocellular carcinoma","prognosis","2026-04-20",{"date":64,"type":31},"2026-04-28",{"date":66,"type":21},"2026-03-31",{"date":68,"type":21},"2035-12-31",{"name":37,"class":38},{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":49,"phases":79,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},"100622015","lll-vs-sdl-for-lbbp-a-non-inferiority-rct-100622015","NCT07378124","LLL vs. SDL for LBBP: A Non-inferiority RCT","Efficacy and Safety Comparison of Lumenless Lead Versus Stylet-driven Lead in Intraoperative Application of Left Bundle Branch Pacing Guided by Continuous Pacing Monitoring With S-V Dissociation as the Primary Outcome: A Non-inferiority, Multicenter, Prospective Randomized Controlled Trial","Inclusion Criteria:\n\n* Symptomatic sick sinus syndrome (SSS);\n* Complete or advanced atrioventricular block (AVB);\n* Patients with heart failure complicated by left bundle branch block (LBBB) and biventricular dyssynchrony;\n* Patients with atrial fibrillation (AF) complicated by refractory rapid ventricular rate who are scheduled for atrioventricular node ablation and permanent pacemaker implantation;\n* Other patients who meet the indications for dual-chamber pacemaker implantation as specified in current guidelines\n\nExclusion Criteria:\n\n* Patients who are ineligible for transvenous cardiac pacemaker implantation due to anatomical abnormalities, infections, or other factors;\n* Patients with existing implantable cardiac electronic devices (ICEDs);\n* Patients who opt for right-sided venous access for any reason;\n* Patients with an expected survival of less than 1 year;\n* Patients who have been enrolled in other clinical trials related to implantable cardiac electronic devices within 3 months prior to enrollment in this study.",{"count":78,"type":21},288,[80],"NA","Left Bundle Branch Pacing (LBBP) has emerged as one of the most commonly used physiological pacing modalities in clinical practice. However, the key determinants of procedural success lie in the accurate intraoperative identification of proper LBB lead positioning and the prevention of cardiac perforation. Our previous research has established a methodology for Lumenless Lead (LLL) implantation under the guidance of continuous pacing monitoring, and this methodology has been further adapted for Stylet-driven Lead (SDL) implantation. The present study is designed as a multicenter, randomized controlled trial, aiming to compare the differences in efficacy and safety between LLL and SDL during LBBP procedures guided by continuous pacing monitoring, with the presence of S-V dissociation serving as the criterion for confirming optimal LBB lead positioning.",[83,84],"Bradycardia","Conduction Block, Atrioventricular","2026-01-31",{"date":87,"type":31},"2026-02-03",{"date":89,"type":21},"2026-01-24",{"date":91,"type":21},"2027-12-31",{"name":37,"class":38},1,{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":102,"enrollmentInfo":103,"targetDuration":4,"studyType":49,"phases":105,"briefSummary":107,"conditions":108,"keywords":110,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":4},"100533103","phase-2-neoadjuvant-sintilimab-plus-anlotinib-therapy-in-ib-iiib-resectable-non-small-cell-lung-cancer-100533103","NCT06221462","Neoadjuvant Sintilimab Plus Anlotinib Therapy in IB-IIIB Resectable Non-small Cell Lung Cancer","Neoadjuvant Sintilimab Plus Anlotinib Therapy in IB-IIIB Resectable Non-small Cell Lung Cancer (PRIORITY): a Prospective Single Center, Open Label, Phase II Study","PRIORITY","Inclusion Criteria:\n\n1. Providing written informed consent prior to initiating the study.\n2. Regardless of sex, aged ≥18 years and ≤75 years.\n3. Histologically confirmed NSCLC.\n4. At least one radiologically measureable lesion according to response evaluation criteria in solid tumors version 1.1(RECIST V1.1).\n5. Treatment-naïve IB-IIIB resectable NSCLC (American Joint Committee on Cancer 8th tumor-node-metastasis classification).\n6. Epidermal growth factor receptor(EFGR)\u002Fanaplastic lymphoma kinase(ALK)\u002FROS proto-oncogene 1(ROS1) wild type NSCLC.\n7. Absence of bleeding risk.\n8. Consent to surgical treatment.\n9. Indication for surgery confirmed by surgeons.\n10. Eastern Cooperative Oncology Group (ECOG) performance status 0-1.\n11. Expected survival time more than 6 months.\n12. Sufficient organ reserve, detailed as follows:(1) the absolute neutrophil count ≥1.5×109\u002FL without the use of granulocyte colony-stimulating factor for the past 14 days prior to the first dose of study drugs;(2) platelet count ≥100×109\u002FL without blood transfusion within the 2 weeks before the enrollment;(3) hemoglobin \\>9g\u002FdL without recent usage of blood transfusion 14 days prior to the study;(4) total bilirubin ≤ 1.5 fold the upper limit of normal (ULN), or total bilirubin \\>1.5 fold ULN but direct bilirubin ≤ 1 fold ULN;(5) aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5×ULN;(6) blood creatinine ≤ 1.5 fold ULN and creatinine clearance (calculated by the Cockcroft-Gault formula) ≥ 60ml\u002Fmin;(7) adequate coagulation function, defined by international normalized ratio (INR) or prothrombin time(PT) less than 1.5 fold ULN;(8) normal thyroid function defined by the normal range of thyroid-stimulating hormone (TSH); otherwise, abnormal level of TSH with normal range of T3(or Ft3) and Ft4;(8) cardiac enzyme profile within the normal limits (merely laboratory abnormity without clinical significance based on investigator's decision is allowed)\n13. For female participants of childbearing age, a urine or serum pregnancy test should be performed within 3 days before receiving the first dose of the study drugs, and the result must be negative. If the urine pregnancy test result is inconclusive, a blood pregnancy test is warranted. Postmenopausal women are defined as those who have been without menstruation for at least 1 year, or have undergone surgical sterilization or hysterectomy.\n14. In the presence of pregnancy risk, all participants (both male and female) are required to use contraceptive measures with an annual failure rate of less than 1% throughout the entire treatment period up to 120 days following the last dose of the study drugs.\n\nExclusion Criteria:\n\nExclusion criteria as follows：\n\n1. Other malignancy rather than NSCLC diagnosed within 5 years prior to the first dose of the study given, except for definitively treated basal cell carcinoma, squamous cell carcinoma of the skin, and\u002For in situ carcinoma.\n2. Enrolled in an ongoing interventional clinical trial, or receiving other study drugs or study medical devices within 4 weeks prior to the first dose of this study drugs.\n3. A history of receiving the following therapies: anti-programmed cell death-1 (anti-PD-1), anti-programmed cell death ligand-1 (anti-PD-L1) or anti-programmed cell death ligand-2 (anti-PD-L2) drugs, or drugs targeting T cell receptor (such as cytotoxic T-lymphocyte-associated protein 4, tumor necrosis factor receptor superfamily member 4 and CD137).\n4. A history of receiving targeted therapy such as anti-vascular endothelial growth receptor (VEGR)\u002F vascular endothelial growth factor receptor (VEGFR), rapidly accelerated fibrosarcoma(RAF), mitogen-activated protein kinase(MAPK), platelet-derived growth factor Receptor(PDGFR) or fibroblast growth factor receptor(FGFR).\n5. Receiving traditional Chinese medication or immunomodulatory drugs (including thymopentin, interferon, interleukin, except for controlling pleural effusion) as systemic therapy within 2 weeks prior to the first dose of the study drugs.\n6. Active systemic auto-immune disease requiring systemic treatment within 2 years prior to the first dose of the study drugs, such as the use of disease-modifying drugs, glucocorticoids or immunosuppressants. Alternative therapies (such as thyroid hormone, insulin, or physiological glucocorticoids used for adrenal or pituitary insufficiency) are not considered as systemic treatment.\n7. Systemic glucocorticoid therapy (excluding nasal, inhaled or other local routes of glucocorticoids) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drugs.\n8. Undergoing allogeneic organ transplant (excluding corneal transplantation) or allogeneic hematopoietic stem cell transplant.\n9. Allergy to the active ingredient or excipients of the study drug, sintilimab.\n10. Having not recovered from any toxicities and\u002For complications caused by prior interventions before the initiation of the study (i.e., ≤ Grade 1 or to baseline, excluding fatigue or hair loss)\n11. Known history of human immunodeficiency virus (HIV) infection.\n12. Untreated active hepatitis B (defined as hepatitis B surface antigen positive with detectable hepatitis B virus(HBV)-DNA copies exceeding the upper limit of normal values).\n13. Active hepatitis C infection.\n14. Receiving a live vaccine within 30 days prior to the first dose of the study drug.\n15. Pregnant or lactating women.\n16. Other investigator's defined uncontrolled systemic disease.","75 Years",{"count":104,"type":21},30,[106],"PHASE2","This is a prospective single-center, open-label, phase II study evaluating the efficacy of sintilimab plus anlotinib as a neoadjuvant regimen in the treatment of IB-IIIB resectable non-small cell lung cancer.",[109],"Carcinoma, Non-Small-Cell Lung",[111,112,113,114],"non small cell lung cancer","Sintilimab","Anlotinib","neoadjuvant therapy","2024-01-23",{"date":117,"type":31},"2024-01-25",{"date":119,"type":21},"2024-02-01",{"date":121,"type":21},"2030-02-01",{"name":37,"class":38},""]